Researchers have enhanced cisplatin’s efficacy in advanced NSCLC by transplanting functional mitochondria from cardiomyocytes ...

Nuvisertib, an oral PIM1 kinase inhibitor from Sumitomo Pharma, has received Orphan Drug Designation from the EMA for ...

A new study published in Cancer Cell reveals that blocking a key nutrient-scavenging process in pancreatic tumors reprograms the tumor microenvironment—reducing fibrosis, enhancing T cell infiltration ...

Antibody-drug conjugates and bispecific antibodies are reshaping the future of targeted therapy in oncology and immunology.

In this exclusive interview, Dr. Raza Bokhari, CEO of Medicus Pharma, introduces SkinJect patch—a cellulose-based microneedle ...

In a breakthrough study published in Science, researchers unveiled an AI-driven platform capable of designing precision ...

The FDA granted Priority Review and Breakthrough Therapy Designation to Imfinzi for resectable gastric and GEJ cancers, based ...

A team of international scientists has uncovered a novel way to boost the cancer-killing power of the immune system’s T cells—by flipping a metabolic switch deep within their mitochondria.

Macrophage checkpoint inhibitors promise a transformative role in cancer immunotherapy; by targeting the “don’t eat me” ...

The START Center for Cancer Research has announced a strategic partnership with Advarra to accelerate and streamline early-phase oncology trials across its global network. By integrating Advarra’s ...

The V Foundation for Cancer Research has appointed Clark Kinlin as Interim CEO, following the departure of Shane Jacobson, who will assume the role of CEO at the American Cancer Society.